Weekly administration of paclitaxel

Theoretical and clinical basis

Paolo Marchetti, Saïk Urien, Giancarlo Antonini Cappellini, Graziana Ronzino, Corrado Ficorella

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The rationale for weekly administration of paclitaxel, which acts on microtubules to arrest mitosis, is that more frequent delivery of moderate doses may achieve greater efficacy than standard doses every 3 weeks, through more sustained exposure of dividing tumor cells to its cytotoxic effects. This dose-dense approach to treatment may inhibit tumor regrowth between cycles and limit the emergence of malignant cell populations resistant to chemotherapy. More frequent exposure to paclitaxel may also enhance its apoptotic and antiangiogenic effects. Paclitaxel activity is considered to be independent of p53 status, in contrast to anticancer drugs that produce lesions on DNA, which achieve a better response if p53 is functional. Weekly therapy also has advantages in terms of improving paclitaxel therapeutic index. Clinical studies show that weekly paclitaxel is effective and that toxicity is acceptable. The response rates of single-agent paclitaxel varied from 21 to 86% in breast cancer, from 20% to 65% in ovarian cancer and from 30% to 56% in non-small cell lung cancer.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
Volume44
Issue numberSUPPL.
Publication statusPublished - Dec 27 2002

Fingerprint

Paclitaxel
Mitosis
Non-Small Cell Lung Carcinoma
Microtubules
Ovarian Neoplasms
Neoplasms
Therapeutics
Breast Neoplasms
Drug Therapy
DNA
Pharmaceutical Preparations
Population

Keywords

  • Clinical efficacy
  • Dose density
  • p53
  • Premedication
  • Rationale
  • Weekly paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Weekly administration of paclitaxel : Theoretical and clinical basis. / Marchetti, Paolo; Urien, Saïk; Cappellini, Giancarlo Antonini; Ronzino, Graziana; Ficorella, Corrado.

In: Critical Reviews in Oncology/Hematology, Vol. 44, No. SUPPL., 27.12.2002.

Research output: Contribution to journalArticle

Marchetti, P, Urien, S, Cappellini, GA, Ronzino, G & Ficorella, C 2002, 'Weekly administration of paclitaxel: Theoretical and clinical basis', Critical Reviews in Oncology/Hematology, vol. 44, no. SUPPL..
Marchetti, Paolo ; Urien, Saïk ; Cappellini, Giancarlo Antonini ; Ronzino, Graziana ; Ficorella, Corrado. / Weekly administration of paclitaxel : Theoretical and clinical basis. In: Critical Reviews in Oncology/Hematology. 2002 ; Vol. 44, No. SUPPL.
@article{79587cc236c147dbafb6ae3b8a6ca8fd,
title = "Weekly administration of paclitaxel: Theoretical and clinical basis",
abstract = "The rationale for weekly administration of paclitaxel, which acts on microtubules to arrest mitosis, is that more frequent delivery of moderate doses may achieve greater efficacy than standard doses every 3 weeks, through more sustained exposure of dividing tumor cells to its cytotoxic effects. This dose-dense approach to treatment may inhibit tumor regrowth between cycles and limit the emergence of malignant cell populations resistant to chemotherapy. More frequent exposure to paclitaxel may also enhance its apoptotic and antiangiogenic effects. Paclitaxel activity is considered to be independent of p53 status, in contrast to anticancer drugs that produce lesions on DNA, which achieve a better response if p53 is functional. Weekly therapy also has advantages in terms of improving paclitaxel therapeutic index. Clinical studies show that weekly paclitaxel is effective and that toxicity is acceptable. The response rates of single-agent paclitaxel varied from 21 to 86{\%} in breast cancer, from 20{\%} to 65{\%} in ovarian cancer and from 30{\%} to 56{\%} in non-small cell lung cancer.",
keywords = "Clinical efficacy, Dose density, p53, Premedication, Rationale, Weekly paclitaxel",
author = "Paolo Marchetti and Sa{\"i}k Urien and Cappellini, {Giancarlo Antonini} and Graziana Ronzino and Corrado Ficorella",
year = "2002",
month = "12",
day = "27",
language = "English",
volume = "44",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

TY - JOUR

T1 - Weekly administration of paclitaxel

T2 - Theoretical and clinical basis

AU - Marchetti, Paolo

AU - Urien, Saïk

AU - Cappellini, Giancarlo Antonini

AU - Ronzino, Graziana

AU - Ficorella, Corrado

PY - 2002/12/27

Y1 - 2002/12/27

N2 - The rationale for weekly administration of paclitaxel, which acts on microtubules to arrest mitosis, is that more frequent delivery of moderate doses may achieve greater efficacy than standard doses every 3 weeks, through more sustained exposure of dividing tumor cells to its cytotoxic effects. This dose-dense approach to treatment may inhibit tumor regrowth between cycles and limit the emergence of malignant cell populations resistant to chemotherapy. More frequent exposure to paclitaxel may also enhance its apoptotic and antiangiogenic effects. Paclitaxel activity is considered to be independent of p53 status, in contrast to anticancer drugs that produce lesions on DNA, which achieve a better response if p53 is functional. Weekly therapy also has advantages in terms of improving paclitaxel therapeutic index. Clinical studies show that weekly paclitaxel is effective and that toxicity is acceptable. The response rates of single-agent paclitaxel varied from 21 to 86% in breast cancer, from 20% to 65% in ovarian cancer and from 30% to 56% in non-small cell lung cancer.

AB - The rationale for weekly administration of paclitaxel, which acts on microtubules to arrest mitosis, is that more frequent delivery of moderate doses may achieve greater efficacy than standard doses every 3 weeks, through more sustained exposure of dividing tumor cells to its cytotoxic effects. This dose-dense approach to treatment may inhibit tumor regrowth between cycles and limit the emergence of malignant cell populations resistant to chemotherapy. More frequent exposure to paclitaxel may also enhance its apoptotic and antiangiogenic effects. Paclitaxel activity is considered to be independent of p53 status, in contrast to anticancer drugs that produce lesions on DNA, which achieve a better response if p53 is functional. Weekly therapy also has advantages in terms of improving paclitaxel therapeutic index. Clinical studies show that weekly paclitaxel is effective and that toxicity is acceptable. The response rates of single-agent paclitaxel varied from 21 to 86% in breast cancer, from 20% to 65% in ovarian cancer and from 30% to 56% in non-small cell lung cancer.

KW - Clinical efficacy

KW - Dose density

KW - p53

KW - Premedication

KW - Rationale

KW - Weekly paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=12244278990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244278990&partnerID=8YFLogxK

M3 - Article

VL - 44

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - SUPPL.

ER -